Drug intelligence / Profile preview

6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine

Development stage: Unknown
Modality: Small Molecules

Overview

6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine is an experimental small molecule belonging to the hypoxanthine class of organic compounds. It acts as a selective inhibitor of cyclin-dependent kinase 2 (CDK2), a key regulator of cell cycle progression. By inhibiting CDK2, this compound may interfere with cellular proliferation, making it a potential candidate for anticancer drug development. As of now, it has not been approved for clinical use and remains in the experimental stage with no reported clinical trials or indications[1][2].

Other names: 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}phenol

Targets

CDK2 (Cyclin-dependent kinase 2)

Beyond the preview

Go deeper on 6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine.

Explore the full profile